Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Cellular and Vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle

dc.contributor.authorGarcia-Diaz, María
dc.contributor.authorKawakubo, Masayoshi
dc.contributor.authorMroz, Pawel
dc.contributor.authorSagristá Gratovil, M. Lluïsa
dc.contributor.authorMora Giménez, Margarita
dc.contributor.authorNonell, Santi
dc.contributor.authorHamblin, Michael R.
dc.date.accessioned2018-11-28T17:58:35Z
dc.date.available2018-11-28T17:58:35Z
dc.date.issued2012-09-10
dc.date.updated2018-11-28T17:58:36Z
dc.description.abstractThe effects of the drug delivery system on the PDT activity, localization, and tumor accumulation of the novel photosensitizer temocene (the porphycene analogue of temoporfin or m-tetrahydroxyphenyl chlorin) were investigated against the P815 tumor, both in vitro and in DBA/2 tumor bearing mice. Temocene was administered either free (dissolved in PEG400/EtOH mixture), or encapsulated in Cremophor EL micelles or in DPPC/ DMPG liposomes, chosen as model delivery vehicles. The maximum cell accumulation and photodynamic activity in vitro was achieved with the free photosensitizer, while temocene in Cremophor micelles hardly entered the cells. Notwithstanding, the micellar formulation showed the best in vivo response when used in a vascular regimen (short drug light interval), whereas liposomes were found to be an efficient drug delivery system for a tumor cell targeting strategy (long drug-light interval). PEG/EtOH formulation was discarded for further in vivo experiments as it provoked lethal toxic effects caused by photosensitizer aggregation. These results demonstrate that drug delivery systems modulate the vascular and cellular outcomes of photodynamic treatments with temocene. © 2012 Elsevier B.V. All rights reserved.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec622026
dc.identifier.issn0168-3659
dc.identifier.pmid22841794
dc.identifier.urihttps://hdl.handle.net/2445/126555
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.jconrel.2012.07.025
dc.relation.ispartofJournal of Controlled Release, 2012, vol. 162, num. 2, p. 355-363
dc.relation.urihttps://doi.org/10.1016/j.jconrel.2012.07.025
dc.rights(c) Elsevier B.V., 2012
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationDrogues
dc.subject.classificationCàncer
dc.subject.otherDrugs of abuse
dc.subject.otherCancer
dc.titleCellular and Vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
622026.pdf
Mida:
3.47 MB
Format:
Adobe Portable Document Format